Pioneered by Our Group, 2015
Novel Haploidentical BMT — Abatacept & PTCy
Our team is one of only four groups in the world to have established an accepted method for Haploidentical Bone Marrow Transplantation. Abatacept and Post-Transplant Cyclophosphamide is our 2015 contribution to the field.
The Challenge
Why Haploidentical BMT is the hardest transplant in medicine
Haploidentical Donor (HID) BMT is immunologically the most challenging procedure in clinical medicine. This was successfully carried out by the Perugia Group led by Aversa and Martelli in 1995. Since then, several approaches to HID-BMT have been tried.
The Four Accepted Methods
The global lineage of Haploidentical BMT
Only four methods are accepted worldwide for carrying out a Haploidentical BMT. Our group is one of them.
By Aversa and Martelli (1995) — the Perugia Group. The first successful Haploidentical BMT, achieved by depleting alpha-beta T cells from the graft to prevent graft-versus-host disease.
By Jones, O'Donnell and Luznick (2008) — the Johns Hopkins approach. Cyclophosphamide given after transplant selectively kills the alloreactive donor T cells.
By Huang and Xao (2010) — the Beijing protocol. Combines anti-thymocyte globulin with multi-agent immunosuppression.
By Chakrabarti and Team (2015) — Bloods R Us / Action Cancer Hospital. Our pioneering contribution to the global Haploidentical BMT toolkit, combining the costimulation blockade of Abatacept with Post-Transplant Cyclophosphamide.
Our Two Protocols
Abatacept & PTCy — Adapted for Two Disease Categories
Our group has developed two protocols based on Abatacept & PTCy — one for non-malignant diseases, one for malignant diseases.
Protocol A — Non-Malignant Diseases
AbaCyS
Abatacept & PTCy with Sirolimus — for Thalassemia, Sickle Cell Anemia, Aplastic Anemia and other non-malignant diseases of the bone marrow.
Protocol B — Malignant Diseases
AbaDCyC
Abatacept & PTCy with short-course Cyclosporine and Abatacept-primed DLI — for Leukemia, Lymphoma, Myeloma and other haematological malignancies requiring Haploidentical BMT.